The FDA has approved Emsam, a selegiline transdermal patch to treat depression in adults, but the drug will have to carry a black-box warning for suicide. The patch is a product of Bristol-Myers Squibb and Somerset Pharmaceuticals, which is a joint venture between Mylan Laboratories and Watson Pharmaceuticals.

Full Story:

Related Summaries